Agios Pharm
$ 33.30
0.45%
14 Apr - close price
- Market Cap 1,942,331,000 USD
- Current Price $ 33.30
- High / Low $ 33.90 / 32.91
- Stock P/E N/A
- Book Value 20.41
- EPS -7.12
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.30 %
- 52 Week High 46.00
- 52 Week Low 22.24
About
Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$43.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -1.85 | -1.78 | -1.93 | -1.55 | -1.74 | -1.47 | -1.69 | -1.45 | -1.72 | -1.64 | -1.51 | -1.47 |
| Estimated EPS | -1.95 | -1.91 | -1.75 | -1.76 | -1.63 | 7.91 | -1.6 | -1.65 | -1.65 | -1.7 | -1.56 | -1.7 |
| Surprise | 0.1 | 0.13 | -0.18 | 0.21 | -0.11 | -9.38 | -0.09 | 0.2 | -0.07 | 0.06 | 0.05 | 0.23 |
| Surprise Percentage | 5.1282% | 6.8063% | -10.2857% | 11.9318% | -6.7485% | -118.5841% | -5.625% | 12.1212% | -4.2424% | 3.5294% | 3.2051% | 13.5294% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.81 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AGIO
2026-04-15 09:09:21
Agios Pharmaceuticals (AGIO), trading at $33.30 with a $1.9b market cap, focuses on rare blood disorder treatments, with its lead product PYRUKYND. Despite a Simply Wall St narrative suggesting a 19.8% undervaluation with a fair value of $41.50 due to potential FDA approval and revenue expansion, its current Price/Sales ratio of 36.1x is significantly higher than industry averages, indicating high expectations for future execution. Investors are presented with mixed signals regarding the company's valuation and the inherent risks associated with its growth prospects.
2026-04-11 21:39:09
Agios Pharmaceuticals' shares rose after the company announced its intention to seek accelerated FDA approval for a label expansion of its drug Pyrukynd (mitapivat). The expanded approval would be for the treatment of non-transfusion-dependent (NTD) alpha- and beta-thalassemia, conditions characterized by reduced or absent hemoglobin production. This move follows positive results from the Phase 3 ENERGIZE and ENERGIZE-T studies, which demonstrated that Pyrukynd significantly improved hemoglobin levels and reduced transfusion burden in adult patients.
2026-04-09 10:09:06
Agios Pharmaceuticals received encouragement from the FDA to pursue accelerated approval for its drug mitapivat for sickle cell disease. This potential accelerated path, coupled with stable operating expenses, could significantly alter the company's risk-reward profile and expedite its path to revenue generation for this key rare-disease treatment. Investors should monitor the upcoming Q1 earnings call for updates on trial funding and expense management, which will impact the timing and scale of future revenue.
2026-04-08 04:10:15
Agios Pharmaceuticals received FDA encouragement for accelerated approval of mitapivat for sickle cell disease, based on its RISE UP Phase 2 and 3 data. This accelerated path, along with stable operating expenses, could significantly impact Agios's investment profile and risk-reward for the mitapivat program. The company's upcoming Q1 earnings call will provide updates on funding and expense management for the new confirmatory trial.
2026-04-07 10:09:07
Agios Pharmaceuticals' Chief Legal Officer, James William Burns, exercised 8,500 performance share units (PSUs) on April 2, 2026, which converted into 8,500 shares of common stock. On the same day, Burns sold 3,280 shares at $34.71 each to cover tax withholding obligations, a transaction pre-arranged under Rule 10b5-1(c). After these transactions, he directly holds 49,306 shares of Agios common stock.
2026-04-07 09:42:20
Agios Pharmaceuticals insider Sarah Gheuens sold 2,940 shares of the company's stock for $102,047 to cover tax obligations related to equity awards. This routine transaction, executed under a pre-arranged Rule 10b5-1 trading plan, reduced her position by 3.53%. Such sales are generally considered neutral by investors as they do not indicate a negative outlook on the company's prospects.
